Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus

Hsieh, Chang‐Hsun; He, Chih-Tseung; Lee, Chien-Hsing; Wu, Ling-Yi; Hung, Yi‐Jen

doi:10.1016/j.metabol.2007.03.018

Cited by 24 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also observe that metformin shows similar results over these parameters: in accord with previous reports, metformin decreases fasting glycaemia, insulin resistance and free fatty acids [25][26][27]. It is not effective in improving glucose tolerance and CRP circulating levels, which is in accord with recent studies in several models of pre-diabetes and type 2 diabetes [26,28].…”

Section: Discussionsupporting

confidence: 91%

“…In addition to these reports, controversy about the potential adverse effects of statins, namely atorvastatin, on glucose metabolism remains, supporting the idea that metabolic actions of atorvastatin, beyond lipid-lowering effects, may be limited [32]. Metformin, in accord with recent data, is not able to increase adiponectin levels [13,[26][27][28]. Combination treatment improved liver inflammation; we hypothesize that a similar effect may occur in adipose tissue and thus increase adiponectin production as only combination treatment significantly increased adiponectin circulating levels.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia

Matafome

Louro

Rodrigues

et al. 2011

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia

Matafome

Louro

Rodrigues

et al. 2011

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Hsieh and cols. (18) reported that two different metformin formulations had no effect on insulin sensitivity and serum visfatin in patients with T2DM, but patients in this study were under anti-diabetic treatment before enrolment. To avoid this potential drawback, Erdem and cols.…”

Section: Effects Of Different Treatments On Visfatin Levels In Sat Pmentioning

confidence: 62%

Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats

Gao

Wang

Pan

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: Visfatin is a recently discovered adipocytokine that contributes to glucose and obesityrelated conditions. Until now, its responses to the insulin-sensitizing agent metformin and to exercise are largely unknown. We aim to investigate the impact of metformin treatment and/or swimming exercise on serum visfatin and visfatin levels in subcutaneous adipose tissue (SAT), peri-renal adipose tissue (PAT) and skeletal muscle (SM) of high-fat-induced obesity rats. Materials and methods:Sprague-Dawley rats were fed a normal diet or a high-fat diet for 16 weeks to develop obesity model. The high-fat-induced obesity model rats were then randomized to metformin (MET), swimming exercise (SWI), or adjunctive therapy of metformin and swimming exercise (MAS), besides high-fat obesity control group and a normal control group, all with 10 rats per group. Zoometric and glycemic parameters, lipid profile, and serum visfatin levels were assessed at baseline and after 6 weeks of therapy. Visfatin levels in SAT, PAT and SM were determined by Western Blot. Results: Metformin and swimming exercise improved lipid profile, and increased insulin sensitivity and body weight reduction were observed. Both metformin and swimming exercise down-regulated visfatin levels in SAT and PAT, while the adjunctive therapy conferred greater benefits, but no changes of visfatin levels were observed in SM. Conclusion: Our results indicate that visfatin down-regulation in SAT and PAT may be one of the mechanisms by which metformin and swimming exercise inhibit obesity.Arq Bras Endocrinol Metab. 2014;58(1):42-7 Keywords Endocrinology; metabolic syndrome; adipocytokine RESUMO Objetivo: A visfatina é uma adipocina recentemente descoberta que contribui com as condições relacionadas à glicose e à obesidade. Até hoje, pouco se sabe da sua resposta à metformina, um agente sensibilizador de insulina, e ao exercício. Nosso objetivo foi investigar o impacto do tratamento com metformina e/ou da natação sobre a visfatina no soro e no tecido adiposo subcutâneo (TAS), tecido adiposo perirrenal (TAP) e músculo esquelético (ME) em ratos com obesidade induzida por dieta com alto teor de gordura. Materiais e métodos: Ratos Sprague-Dawley foram alimentados com uma dieta normal ou com alto teor de gordura por 16 semanas para o desenvolvimento de um modelo de obesidade. Os ratos do modelo de obesidade foram, então, randomizados para a metformina, natação ou terapia de combinação com metformina e natação, além do grupo controle de obesidade induzida por alto teor de gordura e do grupo controle normal. Cada grupo apresentava 10 ratos. Parâmetros zoométricos e glicêmicos, perfil lipídico e níveis de visfatina sérica foram avaliados no momento inicial e após seis semanas de tratamento. Os níveis de visfatina em TAS, TAP e ME foram determinados por Western Blot. Resultados: A metformina e a natação melhoraram o perfil lipídico e aumentaram a sensibilidade à insulina, com redução do peso corporal. Tanto a metformina quanto a natação levaram à regulação para baixo do...

show abstract

“…No changes or even increases in serum visfatin levels have been reported in type 2 diabetes mellitus [23,32,33] and gestational diabetes [34]. Moreover, other insulin-sensitizer drugs do not change visfatin levels [35,36], suggesting that other factors are important regulators of serum visfatin levels and its relationship with glucose metabolism. Therefore, more research is needed to clarify the pathophysiological role of visfatin in diabetes mellitus.…”

Section: Discussionmentioning

confidence: 97%

The Increase in Serum Visfatin After Bariatric Surgery in Morbidly Obese Women is Modulated by Weight Loss, Waist Circumference, and Presence or Absence of Diabetes Before Surgery

et al. 2008

View full text Add to dashboard Cite

show abstract

Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus

Cited by 24 publications

References 43 publications

Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia

Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia

Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats

The Increase in Serum Visfatin After Bariatric Surgery in Morbidly Obese Women is Modulated by Weight Loss, Waist Circumference, and Presence or Absence of Diabetes Before Surgery

Contact Info

Product

Resources

About